Friday, April 24, 2020 11:00:14 PM
Not really, stock may have some pent-up bubbling-under pressure.
[] 97mm Outstanding Shares
[] ~94% Institutionally-owned
[] ~90mm O/S institutionally held
[] So a small, tiny float
[] Stock dropped 50%+ post-Covid
[] $196.40 high (pre-Covid)
[] $98.02 bottom
As the LARGEST National Diagnostic Lab (imho, since COVANCE acquisition) I personally found it irrational that LH would get HAMMERED by over 50%: During a global health crisis & PANDEMIC no less! Especially since LH is a GLOBAL Company with labs in China & around the World.
Anyway, if you look through some of my posts you'll find links, info & recent developments; but NOTHING newsworthy really went on but Coronavirus testing-related progress recently.
They have:
[] An in-home self-swab kit
[] A serology antibody test
[] And their original PCR-Covid medical PCR
Ironically COVID just came & WRECKED the stock price! Which is when my scanners went off. But what's ironic is that LH was founded 40+ years ago as Roche BioMedical. And has deepened those roots as a biological lifesciences company (aka, a REAL PART of the global-crisis SOLUTION) AND enhanced their abilities multi-fold with their COVANCE acquisition.
So the SAME virus that CRUSHED the stock is NOW bringing in lots of additional revenues; as LH is executing AS EXPECTED (at least by me). These revenues should show up in Q2 & even heavier in Q3 as they ramp-up production & testing-capacity.
Additionally:
[] Trump signed $25B aid for commercial lab testing
[] Which should ease raw materials acquisition & facilitate production increases
[] They have the FIRST in-home test-kit in distribution
[] & they should be expanding production & increasing testing substantially in the coming weeks...Starting Monday this week.
So I guess the market is pricing a pps-recovery. The stock had a 26% increase in short-interest (from the previous reporting period), so it's possible they're covering to GET OUT of the WAY.
Which COULD make today's move a TECHNICAL ONE. If you know anything about CHARTS & technical analysis we hurdled QUITE A FEW obstacles:
[] The "U", cup or bowl was "filled"
[] Retraced a bit, & re-tested that U/Gap/Cup @ $150
[] We formed a quick cup-&-handle
[] We filled the GAP (~$151 to $158)
[] Tested, re-tested & surged a bit into the 50DMA
[] Tested & closed above the 50DMA
[] And today,... tested the 200DMA before market-close
[] & then in after-market closed ABOVE it...
That's a LOT of congestion to move UP through & represents as INCREDIBLY bullish imho. Especially going into next week. So we have the 200DMA that needs to get tested, but we could JUST AS EASILY have a GAP UP Monday... In which case, all kinds of scenarios are up for consideration & I won't bore the hell out of anyone with them.
If you check some of my posts I think they might color SOME of what's been shared here so far.... GL
LH
Recent LH News
- Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer • PR Newswire (US) • 05/29/2026 11:00:00 AM
- Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects • PR Newswire (US) • 05/28/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 12:04:15 PM
- Labcorp to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/27/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 08:01:56 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/22/2026 08:26:23 PM
- Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time • PR Newswire (US) • 05/20/2026 11:00:00 AM
- Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems • PR Newswire (US) • 05/12/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 01:51:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/06/2026 02:40:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 06:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 10:57:12 AM
- Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance • PR Newswire (US) • 04/30/2026 10:50:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/28/2026 02:47:03 PM
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA® • PR Newswire (US) • 04/22/2026 11:00:00 AM
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes • PR Newswire (US) • 04/15/2026 11:00:00 AM
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research • PR Newswire (US) • 04/14/2026 11:00:00 AM
- Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide • PR Newswire (US) • 04/13/2026 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 04:10:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 04:01:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 10:54:28 AM
- Labcorp Declares Quarterly Dividend • PR Newswire (US) • 04/09/2026 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:21:45 PM
- Labcorp to Announce First Quarter Financial Results on April 30, 2026 • PR Newswire (US) • 03/31/2026 08:15:00 PM
